VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EORTC CLTF 2021 | Next steps in the development of CXCR4 inhibitors for mycosis fungoides

Lilach Moyal, PhD, Tel Aviv University, Tel Aviv, Israel, outlines the next steps in the development of CXCR4 inhibitors for the treatment of mycosis fungoides (MF). At the moment, research is focused on pre-clinical studies examining the mechanism of action of these agents and explore potential therapeutic candidates including AMD3100 and other novel CXCR4 inhibitors. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter